QCG
LYRA

Quadrant Capital Group’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Quadrant Capital Group’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1
Closed – – 2586
2021
Q2 		$0 Buy
+1
New +$456 ﹤0.01% 2489

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Quadrant Capital Group's LYRA Position: Q3 2021 in Review

Quadrant Capital Group sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2021, closing a stake of 1 share.

Quadrant Capital Group first reported a position in LYRA in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 35 funds tracked by Wall St. Rank hold LYRA as of Q3 2021.

  • Quadrant Capital Group reported no remaining LYRA THERAPEUTICS INC position as of Q3 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 1 LYRA THERAPEUTICS INC share in Q3 2021.
  • Quadrant Capital Group first reported a position in LYRA THERAPEUTICS INC in Q2 2021 and held it in 1 quarter.
  • Quadrant Capital Group's LYRA THERAPEUTICS INC position peaked at $0 in Q2 2021.
  • 35 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2021.

Based on Quadrant Capital Group's 13F filing for Q3 2021, filed 12 Nov 2021.